Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home DAX

Siemens Healthineers Share Buyback Fails to Halt Stock Decline

Dieter Jaworski by Dieter Jaworski
September 2, 2025
in DAX, Healthcare, Market Commentary
0
Siemens Healthineers Stock
0
SHARES
226
VIEWS
Share on FacebookShare on Twitter

Siemens Healthineers shares are experiencing significant downward pressure, trading with notable losses. This decline persists even as the medical technology giant aggressively continues its multi-billion euro share repurchase initiative, creating a situation that is causing uncertainty among investors.

Broad Market Weakness Weighs on Performance

The stock registered a substantial decline of 2.05% in the latest session, dropping to €46.72. This represents a decrease of €0.98 from the previous day’s close. The bearish trend aligns with a broader weakness across the German equity market, where the DAX index concurrently fell by 1.35% to 23,713 points. The prevailing macroeconomic concerns appear to be outweighing the positive impact of company-specific actions.

Uninterrupted Share Repurchase Activity

Despite the falling share price, management is demonstrating its commitment to the buyback program. The initiative, which commenced on March 24, 2025, is being executed as planned. The company’s 23rd interim report, dated September 1, detailed the acquisition of its own shares during the prior trading week from August 25 to August 31.

Should investors sell immediately? Or is it worth buying Siemens Healthineers?

Throughout this period, Siemens Healthineers purchased a total of 154,496 of its own shares. All transactions were executed exclusively via the XETRA trading platform, with the following daily breakdown:

  • August 25: 23,839 shares at an average price of €47.6886
  • August 26: 20,000 shares at an average price of €47.4407
  • August 27: 37,077 shares at an average price of €47.4664
  • August 28: 39,260 shares at an average price of €47.3220
  • August 29: 34,320 shares at an average price of €47.3567

Since the program’s inception, the company has now repurchased a considerable 5,678,190 shares. However, this substantial volume has so far proven insufficient to sustainably reverse the downward trajectory of the stock, leading investors to question when the buyback will begin to exert its intended supportive effect on the share price.

Ad

Siemens Healthineers Stock: Buy or Sell?! New Siemens Healthineers Analysis from February 8 delivers the answer:

The latest Siemens Healthineers figures speak for themselves: Urgent action needed for Siemens Healthineers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Siemens Healthineers: Buy or sell? Read more here...

Tags: Siemens Healthineers
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Vigil Neuroscience Stock
Healthcare

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Next Post
Vertiv Stock

Vertiv's Strategic AI Acquisitions Amid Market Volatility

Applied Blockchain Stock

Strategic Pivot Positions Applied Digital for AI Infrastructure Boom

Tesla Stock

Tesla's Expansion Hits Speed Bumps in Key Markets

Recommended

Cardano Stock

Cardano at a Crossroads: Navigating Critical Support Levels Amid Major Developments

3 months ago
Tesla Stock

Tesla Stock: Musk’s $30B Payday Amid Customer Exodus

6 months ago
Oxford Lane Capital Stock

Oxford Lane Capital Implements Strategic Overhaul with Reverse Split and Buybacks

5 months ago
Ciena Stock

Ciena Shares Hit Record Peak Amid AI Infrastructure Surge

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Trending

DroneShield Stock
Analysis

DroneShield Shares Face Headwinds Despite Record Performance

by Jackson Burston
February 8, 2026
0

A significant disconnect has emerged for DroneShield Ltd. The counter-drone technology company posted explosive growth for fiscal...

Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • DroneShield Shares Face Headwinds Despite Record Performance
  • Rock Tech Lithium: Investors Await the Final Go-Ahead
  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com